Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.66 |
| ▸ | CA1 | P00915 | 6/20 | 0.66 |
| ▸ | CA2 | P00918 | 6/20 | 0.66 |
| ▸ | CA7 | P43166 | 6/20 | 0.66 |
| ▸ | CA9 | Q16790 | 6/20 | 0.66 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.66 |
| ▸ | ESR1 | P03372 | 3/20 | 0.66 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL167161 | 0.86 | CES2 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21636244 | 0.86 | MAPT (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1408429 | 0.82 | LMNA (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1525403 | 0.82 | CES2 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11747306 | 0.82 | ALDH1A1 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL166220 | 0.82 | MAPT (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL696315 | 0.82 | KMT2A (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21636242 | 0.82 | KMT2A (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13909369 | 0.82 | ALDH1A1 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9041402 | 0.82 | MAPT (0.50) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210095074-A1 | POLYOXAZOLIN WITH A PHOTOACTIVATABLE GROUP | BASF SE (DE) | 2021-04-01 | — | — | US | disclosed |
| EP-3649182-A1 | POLYOXAZOLIN WITH A PHOTOACTIVATABLE GROUP | BASF SE (DE) | 2020-05-13 | — | — | EP | disclosed |
| WO-2019007803-A1 | POLYOXAZOLIN WITH A PHOTOACTIVATABLE GROUP | BASF SE (DE) | 2019-01-10 | — | — | WO | disclosed |
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| EP-2444391-B1 | BASE AND RADICAL GENERATOR, COMPOSITION USING SAME AND METHOD FOR CURING SAME | THREE BOND CO LTD (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-5344843-A | Carnitine acryltransferase enzyme inhibitors as antiischemic agents and for cardiovascular disorders | HOFFMAN-LA ROCHE INC. (US) | 1994-09-06 | — | — | US | disclosed |
| US-5298652-A | N-substituted glycines, inhibitors of phospholipase A2 | HOFFMANN-LA ROCHE INC. (US) | 1994-03-29 | — | — | US | disclosed |
| CN-1072677-A | Aromatic amidine derivative and salt thereof | DAIICHI SEIYAKU CO (JP) | 1993-06-02 | — | — | CN | disclosed |
| EP-0540051-A1 | Aromatic amidine derivatives and salts thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-05-05 | — | — | EP | disclosed |
| EP-0512352-A2 | Substituted carboxylic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-11-11 | — | — | EP | disclosed |
| EP-0072932-B1 | PIPERAZINONES, THEIR PREPARATION AND USE | CASSELLA Aktiengesellschaft (DE) | 1990-01-17 | — | — | EP | disclosed |
| US-4598079-A | MEMORY DISORDERS | CASSELLA AKTIENGESELLSCHAFT (DE) | 1986-07-01 | — | — | US | disclosed |
| EP-0072932-A2 | Piperazinones, their preparation and use | CASSELLA Aktiengesellschaft (DE) | 1983-03-02 | — | — | EP | disclosed |
| US-4239779-A | AND AS A HYPOGLYCEMIC AGENT | PFIZER INC. (US) | 1980-12-16 | — | — | US | disclosed |
| US-4219566-A | TREATMENT OF ISCHEMIC HEART DISEASE AND HYPERGLYCEMIA OF DIABETES | PFIZER INC. (US) | 1980-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140065095-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | CA12 4018/4885CA1 1984/4885CA2 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.